Sep. 11 at 5:48 PM
$SENS Senseonics is accelerating into a pivotal new phase of growth. With Eversense 365, the world’s first & only one-year continuous glucose monitoring system, now approved and launched across Europe, Senseonics has expanded its commercial presence beyond the United States into Germany, Italy, Spain, and Sweden, while bringing its European sales and marketing operations in-house. The company delivered record Q2 2026 performance, generating
$14.5 million in revenue, up approximately 120% year over year, with gross margin reaching approximately 59% & full-year revenue guidance raised to
$62–66 million. U.S. revenue surged more than 150%, quarterly shipments reached an all-time high, active prescribers grew approximately 130%, & Eon Care surpassed 90 nurses. With broader European rollout, tender opportunities, automated insulin-delivery compatibility, and the Gemini and Freedom programs ahead, Senseonics is building momentum toward a more connected, global future in diabetes care.
